Kanji Kuma

TL;DR: The preliminary data suggest that papillary microcarcinomas do not frequently become clinically apparent, and that patients can choose observation while their tumors are not progressing, although they are pathologically multifocal and involve lymph nodes in high incidence.

TL;DR: For papillary microcarcinoma, US is an insensitive technique for detecting the central node metastasis, the presence of central nodes metastasis is unrelated to DFS of patients, and when performing lobectomy for PMC involving only one lobe, dissection of the central compartment in the contralateral lobe is optional.

TL;DR: Treatment of thyroid lymphoma does not require resection of all lymphoma tissue or total thyroidectomy, and radiation therapy combined with six courses of CHOP chemotherapy improved the 8-year survival rate to nearly 100% regardless of the histological type of malignancy.

TL;DR: It is suggested that, for papillary microcarcinoma, US-diagnosed lateral metastasis is a strong marker predicting a worse relapse-free survival, FNAB of nodes and FNAb-thyroglobulin measurement are useful tools for evaluating lymph node metastasis, and careful US evaluation is necessary in patients with a tumor measuring ≥ 7 mm or that is located in the upper region of the thyroid both during observation and preoperatively.

TL;DR: Prophylactic MND is recommended for cases of papillary carcinoma demonstrating two or more of the following four characteristics; male gender, age 55 years or older, maximal tumor diameter larger than 3 cm, and massive extrathyroid extension.